Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
11,6 USD | -3,29% | -7,70% | -20,33% |
Omzet 2022 | 25,9 mln. 24,23 mln. | Omzet 2023 | 42,81 mln. 40,05 mln. | Marktkapitalisatie | 17,99 mln. 16,83 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -33 mln. -30,87 mln. | Nettowinst (verlies) 2023 | -24 mln. -22,45 mln. | EV/omzet 2022 | 1,21 x |
Nettoliquiditeiten 2022 | 46,07 mln. 43,09 mln. | Nettoliquiditeiten 2023 | 26,37 mln. 24,66 mln. | EV/omzet 2023 | -0,2 x |
K/w-verhouding 2022 |
-2,32
x | K/w-verhouding 2023 |
-0,67
x | Werknemers | 48 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 1,16% |
Recentste transcriptie over Pieris Pharmaceuticals, Inc.
1 dag | -3,29% | ||
1 week | -7,70% | ||
Lopende maand | -20,85% | ||
1 maand | -20,20% | ||
3 maanden | -9,32% | ||
6 maanden | -40,06% | ||
Lopend jaar | -20,33% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 01-01-10 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 01-12-17 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 59 | 20-09-16 | |
James Geraghty
CHM | Chairman | 70 | 22-05-17 |
Michael Richman
BRD | Director/Board Member | 63 | 17-12-14 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
24-04-24 | 11,6 | -3,33% | 33 297 |
23-04-24 | 12 | +2,67% | 115 544 |
22-04-24 | 11,69 | +0,76% | 23 548 |
19-04-24 | 11,6 | -6,60% | 24 693 |
18-04-24 | 12,42 | -1,18% | 8 306 |
uitgestelde koers Nasdaq, 24 april 2024 om 20:06 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-20,33% | 14,84 mln. | |
-1,52% | 105 mld. | |
+3,61% | 97,5 mld. | |
+1,86% | 22,19 mld. | |
-16,70% | 21,33 mld. | |
-8,49% | 18,68 mld. | |
-42,33% | 16,6 mld. | |
-20,23% | 14,52 mld. | |
+5,59% | 14,09 mld. | |
+28,70% | 10,99 mld. |